

CURRICULUM VITAE

RICHARD A. HAHN, MD, FACC FACP FCCP

PERSONAL INFORMATION

Contact: 1207 Selkirk Lane
Indianapolis, Indiana 46260-1227
(317) 843-1080
(317) 488-8876 (C)
rhahn1207@gmail.com

EDUCATION

Undergraduate: University of Notre Dame
South Bend, Indiana
B.S., Mathematics, 1982
(summa cum laude)

Medical School: Indiana University School of Medicine
Indianapolis, Indiana
M.D., 1986

Residency: Internal Medicine
Methodist Hospital of Indiana, Inc.
1701 North Senate Boulevard
Indianapolis, Indiana 46206
1986-1989

Fellowship: Cardiology
Methodist Hospital of Indiana, Inc.
1701 North Senate Boulevard
Indianapolis, Indiana 46206
1989-1992

PROFESSIONAL INFORMATION

Staff Physician:	Community Health Network Community Hospitals Indianapolis 1500 North Ritter Avenue Indianapolis, Indiana 46219 (317) 355-1411 1992-Present
Private Practice:	Heart and Vascular Care Physicians 1400 N. Ritter Avenue, Suite 500 Indianapolis, Indiana 46219 (317) 355-1234 2013-12/2015, 5/2022-Present Community Heart and Vascular 1400 N. Ritter Avenue, Suite 500 Indianapolis, Indiana 46219 (317) 355-1234 2009-2012 Indiana Heart Associates, Inc. 1400 N. Ritter Avenue, Suite 500 Indianapolis, Indiana 46219 (317) 355-1234 1995-2008 Indianapolis Cardiology Associates, Inc. 1400 N. Ritter Avenue Indianapolis, Indiana 46219 (merged into Indiana Heart Associates, Inc.) 1992-1994
Medical Licensure:	Indiana (National Board of Medical Examiners) #01036130, 1987
Board Certification:	Diplomat of the American Board of Internal Medicine (ABIM), #123870: September 1989 Diplomat of the American Board of Internal Medicine, Cardiovascular Disease: November 1993, November 2001, April 2012, November 2019, May 2021 Member, ABIM Cardiovascular Disease Board Exam Committee, Standard Setting Process, 2016 Member, ABIM Cardiovascular Disease Board Exam Item-Writing Task Force, April 2018 - present Member, Medical Knowledge Self Assessment Program (MKSAP) Peer Review Committee, American College of Physicians, July 2019 - present
Teaching:	Adjunct Professor Indiana University School of Health & Rehabilitation Sciences Department of Physician Assistant Studies December 2018 - present

Adjunct Professor
Butler University College of Pharmacy and Health Sciences
Department of Physician Assistant Studies
August 2021 - present

Volunteer:

Gennesaret Free Clinics, February 1988-present; Medical Director, September 2019 - present

**PROFESSIONAL
MEMBERSHIPS**

Fellow, American College of Cardiology
Fellow, American College of Chest Physicians
Fellow, American College of Physicians
Member, Indiana State Medical Association
Member, Indianapolis Medical Society / Marion County Medical Association

HONORS AND AWARDS

Intern of the Year, 1986-1987
Teaching Resident of the Year, 1987-1988
Chief Administrative Resident / House Staff President 1988-1989
Indianapolis Monthly Magazine Top Doctors, multiple years

**INSTITUTIONAL, DEPARTMENTAL, AND DIVISIONAL
ADMINISTRATIVE RESPONSIBILITIES, COMMITTEE
MEMBERSHIPS AND OTHER ACTIVITIES**

Medical Director, Community Hospitals Indianapolis, Healthy Heart
And Wellness Center, 2009 to 2010
Quality Assurance Committee, Indiana Heart Associates, 1995 to 2008
Executive Committee, Indiana Heart Associates, 2006 to 2008
Finance Committee, Indiana Heart Associates, 1995 to 2005
Chairman, Cardiology Department, Community Hospitals Indianapolis, 2011 to
12/2015
Vice-Chairman, Cardiology Department, Community Hospitals Indianapolis,
1997 to 2004
Associate Medical Director, Research Department, Community Hospitals
Indianapolis, 1992 to 2011
Internal Medicine Department, Community Hospitals Indianapolis,
1992 to 2015
Medical Director, Healthy Heart Center, Indianapolis, 1996 to 2010
Medical Director, IHA/CHVP East Campus, 2003 to 2009, 8/2011 to 12/2014
Medical Director, Community Hospital East Cardiac Rehabilitation Center,
2010 to 2014
Cardiovascular Service Line, Community Hospitals Indianapolis,
1996 to 2008
Cardiovascular Operations, Community Hospitals Indianapolis,
1996 to 2008
Cardiac Catheterization Laboratory Committee, Community Hospitals
Indianapolis, 1994-1997
Pharmacy and Therapeutics Committee, Community Hospitals,
10/2004 to 12/2014

CLINICAL PRACTICE, INTERESTS AND ACCOMPLISHMENTS

I am an internist subspecializing in, and board certified in, cardiovascular diseases, with specialized training in percutaneous revascularization and pacemaker cardiology. However, I very much enjoyed practicing general cardiovascular medicine with a focus on critical care medicine. I also have a special interest in congestive heart failure, and had been instrumental in

CV: Richard A. Hahn, M.D.

establishing a multidisciplinary Healthy Heart Center. This clinic is in the forefront of cost-effective healthcare management, quality-of-life and functional-status improvement, and outcomes research.

I have been engaged as an expert reviewer and witness since the mid-1990's, covering many cases involving law firms, insurance companies, and social security disability. My goal is to apply my cardiovascular education, training, and experience in order to arrive at fair, impartial, and timely opinions for all parties concerned.

CLINICAL RESEARCH PROJECTS

1. "Signal-Averaged Electrocardiography in the Detection of Cardiac Transplant Rejection". Principal Investigator: R.A. Hahn.
2. "Clinical Applications of Synchronized Retroperfusion of Coronary Veins: Protection of Myocardium in High Risk Percutaneous Transluminal Coronary Angioplasty". Co-Investigator: R.A. Hahn.
3. "A Multi-Center Randomized Trial of Subcutaneous Low Molecular Weight Heparin (Logiparin) Versus Continuous Intravenous Unfractionated Heparin for the Initial Treatment of Proximal Vein Thrombosis". Co-Investigator: R.A. Hahn.
4. CARE (Altace): "Trial to Evaluate the "Real World" Safety and 24-Hour Antihypertensive Efficacy of Altace". Principal Investigator: R.A. Hahn.
5. ISIS 4: "The Fourth International Study of Infarct Survival". Co-Investigator: R.A. Hahn.
6. MILRINONE (1): "A Phase IV Study to Evaluate the Effect of Intervention with Intravenous Milrinone or Dobutamine on the Course of Acute Hospital Admissions for Congestive Heart Failure". Co-Investigator: R.A. Hahn.
7. MILRINONE (2): "A Phase IV Study to Evaluate the Occurrence of Ventricular Arrhythmias with Intravenous Milrinone or Dobutamine in Patients with Congestive Heart Failure". Co-Investigator: R.A. Hahn.
8. GUSTO SUBSTUDY: "Effect of Three Thrombolytic Regimens on Infarct Size as Measured by Tc-MIBI Scanning: A GUSTO Substudy". Co-Investigator: R.A. Hahn.
9. EXCEL: "Clinical Investigation of the EXCEL VR Pulse Generator, Models 1120, 1119, AND 1118; and 2035 Hand held Programmer with the EXCEL VR Software Module, Model 270". Cardiac Pacemakers, Inc. Co-Investigator: R.A. Hahn.
10. DIG: "Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure". VA Medical Center. Co-Investigator: R.A. Hahn.
11. RAPID 1: "A Randomized, Open Label, Dose Response Study to Evaluate the Effects of BM 06.022 (r-PA) at Doses of 15 MU, 10 + 5 MU and 10 + 10 MU, Relative to Alteplase (100 mg), on Coronary Artery Patency and Safety in Patients with Acute Myocardial Infarction." Boehringer Mannheim. Co-investigator: R.A. Hahn.
12. CARS: "A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Fixed Low Doses of Coumadin Plus Aspirin to Aspirin Alone in the Prevention of Reinfarction, Cardiovascular Death, and Stroke in Post-Myocardial Infarction Patients." DuPont Merck. Principal Investigator: R.A. Hahn.
13. SELUTE: "Clinical Investigation of the CPI Steroid Eluting Lead, Models 4185 and 4285." Guidant. Co-Investigator: R.A. Hahn.
14. CRAC: "A Prospective Randomized Trial of "Compliant" Vs. "Non-Compliant" Balloons in Elective Angioplasty: An Evaluation of Coronary Artery Disease." UAMS. Co-Investigator: R.A. Hahn.
15. HIRULOG: "A Multicenter Double-Blind, Randomized Study to Compare the Safety and Efficacy of BG8967 With Heparin In Patients With Unstable Angina Undergoing Percutaneous Transluminal Coronary Angioplasty." Biogen, Inc. Co-Investigator: R.A. Hahn.
16. RAPID 2: "A Randomized, Open Label, Multicenter, Angiographic Study to Compare the Effects of 10 + 10 MU r-PA with Front-Loaded Alteplase in Patients With Acute Myocardial Infarction." Boehringer Mannheim. Co-Investigator: R.A. Hahn.
17. CARDIZEM/DIG Study: "Comparison of the Efficacy, Safety and Economic Outcomes of Cardizem Injectable and Digoxin IV in the Treatment of Atrial Fibrillation and Atrial Flutter". Marion Merrell Dow. Co-investigator: R.A. Hahn.
18. ALLHAT: "The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial." NIH. Co-investigator: R.A. Hahn.
19. ETAB: "A Phase 2, Dose-Ranging Study of LY297141 in Patients with Unstable Angina/Non-Q-Wave Myocardial Infarction." Lilly. Co-Investigator: R. A. Hahn.
20. LAMIFIBAN: "A randomized, double-blind, placebo-controlled study with two doses of lamifiban (Ro 44-9883) with or without heparin, in patients with Acute Coronary Syndrome without ST-segment elevation (unstable angina, non-Q wave myocardial infarction)." Hoffmann-LaRoche. Principal Investigator: R. A. Hahn.

CV: Richard A. Hahn, M.D.

21. PARAGON A: "Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network." Hoffmann-LaRoche. Principal Investigator: R.A. Hahn.
22. INTIME 1: "Multicenter, Double-Blind, Randomized, Dose-Ranging Trial of BMS-200,980 in Subjects with Acute Myocardial Infarction". Bristol Myers Squibb. Co-Investigator: R.A. Hahn.
23. BIOSTENT-9501: "Phase I/II of Biostent™ Administered Immediately Post-PTCA by a Delivery Catheter." NeoRx. Co-Investigator: R. A. Hahn
24. PASSIVE PLUS: "Passive Plus™ Model 1342T/1346T Bipolar Steroid Eluting, Passive Fixation, Endocardial Pacing Leads". Pacesetter. Co-Investigator: R.A. Hahn.
25. AFFIRM: "Atrial Fibrillation Follow-Up Investigation of Rhythm Management." NIH. Principal Investigator: R. A. Hahn
26. CARVEDILOL (SKB 105517): "An Open-Label Evaluation of Carvedilol in Patients with Congestive Heart Failure (NYHA Class II-IV)". SmithKline Beecham. Co-investigator: R.A. Hahn.
27. PEACE: "Prevention of Events with Angiotensin Converting Enzyme Inhibition." NIH. Co-Investigator: R.A. Hahn
28. "ADDVENT™ Model 2060LR Pulse Generator and AVPLUS™ Model 1358C Steroid Eluting Single Pass AV Pacing Lead". St. Jude Medical. Principal Investigator: R.A. Hahn.
29. TECBEST (TEC® Before Stent): "Randomized Trial of Extraction Atherectomy and Stenting versus Primary Stenting for the Treatment of Saphenous Vein Graft Disease." Interventional Technologies. Co-Investigator: R.A. Hahn.
30. NATRECOR (I): "A Randomized, Open-label, Active-controlled, Multicenter Phase III Safety Study of Two Doses of NATRECOR® hBNP Administered as a Continuous Infusion in the Treatment of Decompensated CHF." SCIOS. Co-Investigator: R.A. Hahn
31. PRAISE 2 (Prospective Randomized Amlodipine Survival Evaluation - 2): "A randomized, double-blind, dose titration, parallel group, placebo-controlled study to evaluate the effect of amlodipine on survival in patients with congestive heart failure." Pfizer. Principal Investigator: R.A. Hahn
32. BMS-CV137-013: "Pilot Evaluation of the Effects of the DMP Inhibitor BMS-186716 on Functional Capacity in Subjects with Heart Failure." Bristol Myers Squibb. Co-Investigator: R.A. Hahn.
33. BMS-CV137-018: "Evaluation of the Safety/Tolerability of Long-Term Treatment with the DMP Inhibitor BMS-186716 or Lisinopril in Subjects with Heart Failure." Bristol Myers Squibb. Co-Investigator: R. A. Hahn
34. ENDOTHELIN (SB209670): "Intravenous SB209670 Compared to Placebo to Prevent Radiocontrast Induced Acute Renal Failure in Patients at Risk." SmithKline Beecham. Co-Investigator: R. A. Hahn.
35. SCD-HeFT: "Sudden Cardiac Death Heart Failure Trial of Prophylactic Amiodarone or Implantable Defibrillator Therapy V. Placebo." NIH. Principle Investigator: R.A. Hahn
36. ASSENT II (Assessment of the Safety and Efficacy of a New Thrombolytic agent): "A phase III, randomized, double-blind, parallel-group, international trial of single bolus of TNK-tissue plasminogen activator (TNK-tPA) versus accelerated infusion of rt-PA (Alteplase, Activase) in acute myocardial infarction." Boehringer Ingelheim. Co-Investigator: R.A. Hahn
37. SYMPHONY: "A Phase III, multicenter, international, randomized, double-blind, aspirin-controlled study to evaluate the efficacy and safety of sibrifiban (Ro 48-3657), an oral platelet glycoprotein IIb/IIIa antagonist, as therapy for the prevention of secondary vascular events in patients after Acute Coronary Syndrome." Hoffmann-LaRoche. Co-Investigator: R.A. Hahn
38. ALIVE (Azimilide Post-Infarct SurVival Evaluation Trial): "A Double-Blind, Placebo-Controlled, Parallel Design Study to Determine the Effect of 75 or 100mg of Orally Administered Azimilide Dihydrochloride versus Placebo on Survival in Recent Post-Myocardial Infarction Patients at Risk of Sudden Death." Proctor & Gamble. Co-Investigator: R.A. Hahn
39. NATRECOR (II): "NatreCOR® (Nesiritide) Versus Dobutamine Therapy for Symptomatic, Decompensated CHF: A Safety Study Using 24-Hour Holter Monitoring." SCIOS. Co-Investigator: R.A. Hahn
40. SMYLE (Safety of Moxonidine in a Year Long Evaluation): "Open Label Safety Study of Sustained-Release (SR) Moxonidine in Stage 1 and Stage 2 Hypertension." Lilly. Co-Investigator: R.A. Hahn.
41. 2nd SYMPHONY: "A Phase III, multicenter, international, randomized, double-blind, aspirin-controlled trial to evaluate the efficacy and safety of two regimens with Xubix™ (sibrifiban; Ro 48-3657), an oral platelet glycoprotein IIb/IIIa receptor antagonist, as therapy for the long term prevention of secondary vascular events in patients after an Acute Coronary Syndrome." Hoffmann LaRoche. Co-Investigator: R.A. Hahn
42. OVERTURE: "Omapatrilat Versus Enalapril Randomized Trial Of Utility In Reducing Events" Protocol Number: CV137-068. Bristol-Myers Squibb. Co-Investigator: R.A. Hahn
44. VMAC: "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of NatreCOR® (Nesiritide) Compared with Nitroglycerin Therapy for Symptomatic Decompensated CHF". Scios, Inc. 704.339. Co-Investigator: R.A. Hahn

CV: Richard A. Hahn, M.D.

45. EPHESUS: "A Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Eplerenone in Patients with Heart Failure Following Acute Myocardial Infarction" Protocol Number: IE3-99-02-035. G.D. Searle. Co-Investigator: R.A. Hahn
46. "Multicenter, Double-Blind, Randomized, Dose-Ranging Trial of BMS-200, 980 in Subjects with Acute Myocardial Infarction". Co-Investigator: R.A. Hahn.
47. GUSTO III: "The Global Use of Strategies To Open Coronary Arteries Project: A Randomized Trial of Reteplase (r-PA) VERSUS Accelerated Alteplase (t-PA) for the Treatment of Acute Myocardial Infarction". Boehringer Mannheim. Co-Investigator: R.A. Hahn.
48. ECDOLTHELIN (SB209670): "Intravenous SB209670 Compared to Placebo to Prevent Radiocontrast Induced Acute Renal Failure in Patients at Risk." SmithKline Beecham. Co-Investigator: R.A. Hahn.
49. COMMA: "A Randomized Double-Blind, Placebo-Controlled Study of Two Intravenous Dosing Regimens of H5G1.1-SCFV in Patients with Acute Myocardial Infarction Undergoing Percutaneous Transluminal Coronary Angioplasty Reperfusion Therapy." Principal Investigator: R. A. Hahn
50. PROVE IT: "Pravastatin or Atorvastatin Evaluation and Infection Therapy." Principal Investigator: R.A. Hahn
51. FUSION II: Follow-Up Serial Infusions Of Natrecor (nesiritide) for the Management of Patients with Heart Failure. Principal Investigator: R.A. Hahn.
52. The AMADEUS trial: A multicenter, randomized, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous idraparinux (SanOrg 34006) with adjusted-dose oral vitamin-K antagonists in the prevention of thromboembolic events in patients with atrial fibrillation. Protocol 64720. Principal Investigator: R.A. Hahn.
53. IMPROVE-IT - A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. Principal Investigator: R.A. Hahn
54. TRACER - A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome. Principal Investigator: R.A. Hahn.
55. The TRILOGY ACS Study- A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects With Unstable Angina/Non-ST-Elevated Myocardial Infarction (UA/NSTEMI) Who are Medically Managed. Co-Investigator: R.A. Hahn.
56. EXAMINE; A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome. Principle Investigator: R. A. Hahn
57. The TRANSLATE-ACS Study: Treatment with ADP receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome. Sub-Investigator: R. A. Hahn
58. DRONE: A Placebo-Controlled, Double-Blind, Randomized, Multi-center Study to Assess the Effects of Dronedarone 400 mg BID on Cardiac Geometry and Function in Patients with Atrial Fibrillation and Left Atrial Enlargement. Principle Investigator: R.A. Hahn
59. RIVER PCI Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization. Principle Investigator: R. A. Hahn.

CV: Richard A. Hahn, M.D.

Updated 05/2022